Celon Pharma S.A. (WSE: CLN) is an innovative Polish biopharmaceutical company focused on research, development, and production of proprietary therapies in oncology, psychiatry, and inflammatory diseases. With in-house R&D capabilities and a growing clinical pipeline, Celon aims to commercialize novel molecules for global markets. Its dual strategy of proprietary drug development and generic manufacturing ensures revenue diversification. The company offers investors exposure to high-potential biotech innovation anchored in local production and scientific expertise.
Derniers articles sur les actions